In the U.S. someone has a heart attack or stroke every 40 seconds, and nearly one in three of these patients will have another cardiovascular (CV) event; however some patients are being denied the needed treatments.
New data being presented at the 2018 ACC Scientific Sessions explores the clinical impact due to restrictive insurance practices for access to PCSK9 inhibitors.
We spoke with Seth J. Baum, M.D., President of the American Society for Preventive Cardiology, to discuss the challenges that patients experience when to trying to receive a PCSK9 inhibitor prescribed by their doctors.
The information, advice and answers displayed in The Rhode Show section of WPRI.com are those of individual sponsors and not WPRI-TV/Nexstar Media Group, Inc. WPRI.com presents this content on behalf of each participating Rhode Show sponsor. Sponsored content is copyrighted to its respective sponsor unless otherwise indicated.